Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats

Clinical and Experimental Immunology

Volumn 138, Issue 3, 2004, Pages 430-438

  Morgan, B Paul ^a   Griffiths, M ^a   Khanom, H ^a   Taylor, S M ^b   Neal, J W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Chemokines; Complement; Neuroimmunology; Rodent

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT MEMBRANE ATTACK COMPLEX; PEPTIDE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOTAXIS; COMPLEMENT ACTIVATION; DEMYELINATION; DISEASE COURSE; DISEASE MODEL; ENCEPHALITIS; MALE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; COMPLEMENT ACTIVATION; ENCEPHALOMYELITIS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; NEUTROPHILS; RATS; RATS, INBRED LEW; RECEPTOR, ANAPHYLATOXIN C5A; SPINAL CORD;

EID: 9644302961     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02646.x     Document Type: Article

References (57)

1. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-66.
2. Morgan BP, Gasque P, Singhrao SK, Piddlesden SJ. Role of complement in inflammation and injury in the nervous system. Exp Clin Immunogenet 1997; 14:19-23.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343:938-52.
4. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan BP, Lassmann H. Multiple sclerosis, in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43:465-71.
5. Kornek B, Storch MK, Weissert R et al. Multiple sclerosis and chronic autoimmune encephalomyelitis. a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157:267-76.
6. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118:1583-92.
7. Waxman SG. Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 1998; 338:323-5.
8. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions, implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-17.
9. Bornstein MB, Appel H. Tissue culture studies of demyelination. Ann NY Acad Sci 1965; 122:280-6.
10. Liu WT, Vanguri P, Shin ML. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J Immunol 1983; 131:778-82.
11. Scolding NJ, Morgan BP, Houston A, Campbell AK, Linington C, Compston DA. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci 1989; 89:289-300.
12. Linington C, Lassmann H, Morgan BP, Compston DA. Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol 1989; 79:78-85.
13. Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15:307-16.
14. Linington C, Morgan BP, Scolding NJ, Wilkins P, Piddlesden SJ, Compston DA. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989; 112:895-911.
15. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152:5477-84.
16. Leenaerts PL, Stad RK, Hall BM, Van Damme BJ, Vanrenterghem Y, Daha MR. Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol 1994; 97:478-82.
17. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168:458-65.
18. Heideman M, Hugli TE. Anaphylatoxin generation in multisystem organ failure. J Trauma 1984; 24:1038-43.
19. Mulligan MS, Schmid E, Beck-Schimmer B et al. Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest 1996; 98:503-12.
20. Casque P, Singhrao SK, Neal JW, Gotze O, Morgan BP. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997; 150:31-41.
21. Sayah S, Patte C, Casque P, Chan P, Ischenko A, Vaudry H, Fontaine M. Characterization of rat C5a anaphylatoxin receptor (CSaR): cloning of rat CSaR cDNA and study of CSaR expression by rat astrocytes. Brain Res Mol Brain Res 1997; 48:215-22.
22. Van Beek J, Bernaudin M, Petit E, Casque P, Nouvelot A, MacKenzie ET, Fontaine M. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp Neurol 2000; 161:373.
23. Akatsu H, Abe M, Miwa T, Tateyama H, Maeda S, Okada N, Kojima K, Okada H. Distribution of rat C5a anaphylatoxin receptor. Microbiol Immunol 2002; 46:863-74.
24. Nataf S, Davoust N, Barnum SR. Kinetics of anaphylatoxin C5a receptor expression during experimental allergic encephalomyelitis. J Neuroimmunol 1998; 91:147-55.
25. Stahel PF, Kossmann T, Morganti-Kossmann MC, Hans VHJ, Barnum SR. Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats. Mol Brain Res 1997; 50:205-12.
26. Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR. Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J Neurol Sci 1996; 144:135-41.
27. Stahel PF, Kariya K, Shohami E, Barnum SR, Eugster H, Trentz O, Kossmann T, Morganti-Kossmann MC. Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. J Neuroimmunol 2000; 109:164-72.
28. Farkas I, Takahashi M, Fukuda A et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol 2003; 170:5764-71.
29. Mulligan MS, Schmid E, Till GO et al. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol 1997; 158:1857-61.
30. Kroshus TJ, Rollins SA, Dalmasso AP et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60:1194-202.
31. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Malis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93:8563-8.
32. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1995; 42:1965-74.
33. Short A, Wong AK, Finch AM, Haaima G, Shiels IA, Fairlie DP, Taylor SM. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol 1999; 126:551-4.
34. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46:2476-85.
35. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003; 171:5514-20.
36. Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP. Small molecular probes for G-protein-coupled C5a receptors: Conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem 1998; 41:3417-25.
37. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130:443-54.
38. van Waesberghe JH, Kamphorst W, De Groot CJ et al. Axonal loss in mutiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747-54.
39. Freeman GE, Dalton CA, Brooks PM. A Nycodenz gradient method for the purification of neutrophils from the peripheral blood of rats. J Immunol Meth 1991; 139:241-9.
40. Arumugam TV, Woodruff TM, Stocks SZ et al. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol 2004; 40:934-41.
41. Hugli TE. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol 1981; 1:321-66.
42. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999; 162:4018-23.
43. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2:95-101.
44. Minami M, Satoh M. Chemokines and their receptors in the brain: pathophysiological roles in ischemic brain injury. Life Sci 2003; 74:321-7.
45. Welch TR, Frenzke M, Witte D, Davis AE. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol 2002; 130:43-8.
46. Reiman R, Gerard C, Campbell IL, Barnum SR. Disruption of the C5a receptor gene fails to protect against experimental allergic encephalo-myelitis. Eur J Immunol 2002; 32:1157-63.
47. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 2000; 165:5867-73.
48. Calida DM, Constaritinescu C, Purev E, Zhang GX, Ventura ES, Lavi E, Rostami A. Cutting edge. C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol 2001; 166:723-6.
49. Mead RJ, Neal JW, Griffiths MR, Linington C, Botto M, Lassmann H, Morgan BP. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Invest 2004; 84:21-8.
50. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143:555-64.
51. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3:569-81.
52. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1 alpha or its CCR5 receptor. Eur J Immunol 2000; 30:1410-5.
53. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR) 2. J Exp Med 2000; 192:1075-80.
54. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192:899-905.
55. Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 1999; 97:166-72.
56. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Morgan BP. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and non-myeloid cells in inflamed human CNS. Analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998; 160:3543-54.
57. Monsinjon T, Casque P, Ischenko A, Fontaine M. C3a binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. FEBS Lett 2001; 487:339-46.